AI
AKBA icon

Atom Investors’s Akebia Therapeutics AKBA Stock Holding History

Atom Investors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,633
Closed -$42.7K – 567
2025
Q3 		$42.7K Buy
+15,633
New +$52K ﹤0.01% 578
2025
Q1 		– Sell
-12,903
Closed -$24.5K – 495
2024
Q4 		$24.5K Sell
12,903
-1,664
-11% -$2.89K ﹤0.01% 479
2024
Q3 		$19.2K Buy
+14,567
New +$19.5K ﹤0.01% 455
2020
Q3 		– Sell
-251,885
Closed -$3.42M – 503
2020
Q2 		$3.42M Buy
251,885
+27,116
+12% +$281K 0.22% 84
2020
Q1 		$1.7M Buy
+224,769
New +$1.75M 0.15% 124

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Atom Investors's AKBA Position: Q4 2025 in Review

Atom Investors sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 15,633 shares — an estimated $42.7K sold.

Atom Investors first reported a position in AKBA in Q1 2020 and held it in 5 quarters. The position peaked at $3.42M in Q2 2020. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

  • Atom Investors reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Atom Investors sold 15,633 Akebia Therapeutics shares in Q4 2025, an estimated $42.7K.
  • Atom Investors first reported a position in Akebia Therapeutics in Q1 2020 and held it in 5 quarters.
  • Atom Investors's Akebia Therapeutics position peaked at $3.42M in Q2 2020.
  • 165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.